Ganymed reports IMAB362 data for gastroesophogeal cancer

Ganymed Pharmaceuticals AG (Mainz, Germany) said IMAB362 led to a disease control rate of 48%, including four partial responses and six cases of stable disease in patients with advanced CLND18.2-positive gastroesophageal cancer. The data were from a per protocol population of 21 of the 54 patients in the open-label Phase IIa trial. Patients received 600 mg/m2 IMAB362 as monotherapy every two weeks for five cycles. Median PFS was 102 days. ...